ELTP

Elite Pharmaceuticals, Inc. [ELTP] Stock Forecast

Q: What is Elite Pharmaceuticals, Inc. stock symbol ?

Elite Pharmaceuticals, Inc. is a US stock, located in Northvale of Nj and trading under the symbol ELTP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ELTP Stock Summary

Earnings have grown 105767.55% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

ELTP has less than 1 year of cash runway

Top 10 Correlated Stocks

ELTP

In the News

ELTP Financial details

Company Rating

Buy

Market Cap

142.49M

Income

15.55M

Revenue

47.32M

Book val./share

0.05

Cash/share

0.01

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

29 Jun 2024

P/E

8.45

Forward P/E

PEG

1.14

P/S

3.67

P/B

3.34

P/C

13.35

P/FCF

-139.22

Quick Ratio

Current Ratio

1.82

Debt / Equity

0.17

LT Debt / Equity

0.07

EPS (TTM)

0.02

EPS next Y

EPS next Q

EPS this Y

49331.82%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

438.13%

Revenue Q/Q

9.76%

EPS Q/Q

-95.24%

SMA20

SMA50

-26.32%

SMA100

Inst Own

0.01%

Inst Trans

ROA

25%

ROE

53%

ROC

0.1%

Gross Margin

48%

Oper. Margin

12%

Profit Margin

43%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.03-0.21

52W High

52W Low

RSI

34.43

Rel Volume

0.06

Avg Volume

1.34M

Volume

85.71K

Perf Week

-5.29%

Perf Month

-14.35%

Perf Quarter

7.06%

Perf Half Y

33.5%

Beta

-0.144

Volatility

0%, 0.01%

Prev Close

-1.69%

Price

0.1335

Change

1.14%

ELTP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.01	0.02	0.03	0.03	33.72
Net income per share	-0.01	0	0.01	0.01	4.35
Operating cash flow per share	-0.01	0	0	0.01	0
Free cash flow per share	-0.01	0	0	0.01	0
Cash per share	0	0	0	0.01	0.01
Book value per share	0.01	0.01	0.02	0.02	0.03
Tangible book value per share	0.01	0	0.01	0.02	0.02
Share holders equity per share	0.01	0.01	0.02	0.02	0.03
Interest debt per share	0.01	0.01	0	0	-1.09
Market cap	81.42M	58.26M	56.58M	35.32M	29.37M
Enterprise value	83.12M	61.16M	55.77M	29.57M	25.43M
P/E ratio	-8.77	-26.01	11.12	3.97	0.01
Price to sales ratio	10.76	3.24	2.23	1.09	0
POCF ratio	-11.99	-32.48	17.72	5.43	8.8
PFCF ratio	-11.95	-31.86	19.76	5.88	-12.25
P/B Ratio	7.14	5.47	3.5	1.4	1.01
PTB ratio	7.14	5.47	3.5	1.4	1.01
EV to sales	10.98	3.4	2.2	0.92	0
Enterprise value over EBITDA	-10.55	-80.17	15.36	4.54	0.01
EV to operating cash flow	-12.24	-34.09	17.46	4.54	7.62
EV to free cash flow	-12.2	-33.44	19.47	4.92	-10.6
Earnings yield	-0.11	-0.04	0.09	0.25	150.13
Free cash flow yield	-0.08	-0.03	0.05	0.17	-0.08
Debt to equity	0.35	0.38	0.15	0.11	0.13
Debt to assets	0.16	0.16	0.09	0.08	0.1
Net debt to EBITDA	-0.22	-3.8	-0.22	-0.88	0
Current ratio	1.28	1.19	2.1	2.82	2.75
Interest coverage	-24.81	-6.42	8.11	26.44	-1.82
Income quality	0.73	0.8	0.63	0.73	0.94
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.43	0.19	0.13	0.14	0.15
Research and developement to revenue	1	0.31	0.2	0.13	0.18
Intangibles to total assets	0.27	0.27	0.25	0.19	0.16
Capex to operating cash flow	0	0.02	-0.1	-0.08	-1.72
Capex to revenue	0	0	-0.01	-0.02	0
Capex to depreciation	-0.02	-0.02	-0.22	-0.35	-4.27
Stock based compensation to revenue	0.23	0.06	0.04	0.02	0
Graham number	0.06	0.03	0.05	0.07	1.67
ROIC	-0.57	-0.15	0.14	0.22	68.18
Return on tangible assets	-0.52	-0.12	0.26	0.31	127.62
Graham Net	-0.01	-0.01	0	0	0
Working capital	1.95M	1.61M	6.38M	12.17M	13.68M
Tangible asset value	4.76M	4.02M	9.52M	18.59M	22.62M
Net current asset value	-4.15M	-4.05M	2.16M	8.93M	9.57M
Invested capital	0.35	0.38	0.15	0.11	0.13
Average receivables	998.84K	2.71M	3.8M	3.28M	3.08M
Average payables	1.52M	1.48M	1.25M	1.18M	1.94M
Average inventory	4.71M	4.33M	4.58M	5.88M	8.15M
Days sales outstanding	63.75	83.3	50.28	34.6	0.03
Days payables outstanding	106.79	57.5	25.11	29.9	0.05
Days of inventory on hand	350.62	150.96	135.4	140.87	0.2
Receivables turnover	5.73	4.38	7.26	10.55	11.04K
Payables turnover	3.42	6.35	14.54	12.21	7.18K
Inventory turnover	1.04	2.42	2.7	2.59	1.84K
ROE	-0.81	-0.21	0.32	0.35	152.27
Capex per share	0	0	0	0	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.01	0.01	0.01	0.01	0.02
Net income per share	0	0	0	0.01	0
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0.02	0.01	0.01	0.01	0.01
Book value per share	0.03	0.03	0.03	0.04	0.05
Tangible book value per share	0.02	0.02	0.02	0.04	0.04
Share holders equity per share	0.03	0.03	0.03	0.04	0.05
Interest debt per share	0.02	0	0.01	0.01	0.01
Market cap	29.95M	29.4M	38.83M	95.12M	142.07M
Enterprise value	28.02M	25.46M	37.59M	94.12M	144.14M
P/E ratio	2.52	-5.98	8.5	1.59	50.28
Price to sales ratio	3.24	3.4	4.32	6.72	9.14
POCF ratio	-52.73	9.9	-14.33	-403.16	-58.99
PFCF ratio	-52.67	12.09	-14.33	-403.16	-50.48
P/B Ratio	0.99	1.02	1.29	2.11	3.06
PTB ratio	0.99	1.02	1.29	2.11	3.06
EV to sales	3.03	2.95	4.19	6.65	9.28
Enterprise value over EBITDA	12.28	96.91	19.35	41.61	37.12
EV to operating cash flow	-49.34	8.58	-13.87	-398.91	-59.85
EV to free cash flow	-49.28	10.47	-13.87	-398.91	-51.21
Earnings yield	0.1	-0.04	0.03	0.16	0
Free cash flow yield	-0.02	0.08	-0.07	0	-0.02
Debt to equity	0.53	0.13	0.26	0.17	0.17
Debt to assets	0.3	0.1	0.17	0.11	0.1
Net debt to EBITDA	-0.84	-15.02	-0.64	-0.44	0.53
Current ratio	4.98	2.75	2.27	1.82	1.94
Interest coverage	6.07	-1.17	13.42	14.76	29.04
Income quality	-0.19	-2.42	-2.37	-0.02	-3.41
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.13	0.09	0.19	0.11	0.11
Research and developement to revenue	0.16	0.28	0.13	0.18	0.09
Intangibles to total assets	0.13	0.16	0.14	0.09	0.08
Capex to operating cash flow	0	-0.18	0	0	0.17
Capex to revenue	0	-0.06	0	0	-0.03
Capex to depreciation	0	-1.53	0	0	-1.16
Stock based compensation to revenue	0.02	0.01	0	0	0.04
Graham number	0.04	0.03	0.03	0.12	0.03
ROIC	0.04	-0.02	0.04	-0.2	-0.49
Return on tangible assets	0.06	-0.04	0.03	0.23	0.01
Graham Net	0	0	0	0	0
Working capital	26.51M	13.68M	15.37M	15.65M	18M
Tangible asset value	23.54M	22.62M	23.78M	38.75M	40.07M
Net current asset value	10.62M	9.57M	11.06M	9.1M	8.87M
Invested capital	0.53	0.13	0.26	0.17	0.17
Average receivables	4.89M	4.32M	4.65M	8.35M	13.25M
Average payables	1.6M	1.96M	2.16M	2.74M	3.25M
Average inventory	8.04M	9.08M	10.36M	13.2M	14.77M
Days sales outstanding	53.96	32.23	62.15	66.72	92.73
Days payables outstanding	30.59	42.35	39.9	42.13	29.43
Days of inventory on hand	178.76	165.3	237.65	177.71	145.82
Receivables turnover	1.67	2.79	1.45	1.35	0.97
Payables turnover	2.94	2.13	2.26	2.14	3.06
Inventory turnover	0.5	0.54	0.38	0.51	0.62
ROE	0.1	-0.04	0.04	0.33	0.02
Capex per share	0	0	0	0	0

ELTP Frequently Asked Questions

What is Elite Pharmaceuticals, Inc. stock symbol ?

Elite Pharmaceuticals, Inc. is a US stock , located in Northvale of Nj and trading under the symbol ELTP

What is Elite Pharmaceuticals, Inc. stock quote today ?

Elite Pharmaceuticals, Inc. stock price is $0.1335 today.

Is Elite Pharmaceuticals, Inc. stock public?

Yes, Elite Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.34M
Market Capitalization 142.49M
Employee 53
CEO Mr. Nasrat Hakim
Headquarters Northvale,NJ,US
IPO Date 2000-02-24
Website https://www.elitepharma.com

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.